METHYL 3-BROMO-5-(4-CHLOROPHENYL)-4-CYANO-1H-PYRROLE-2-CARBOXYLATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KVEVURFUAFTZBV-UHFFFAOYSA-N
Smiles	COC(=O)c1[nH]c(c2ccc(Cl)cc2)c(C#N)c1Br
InChI	InChI=1S/C13H8BrClN2O2/c1-19-13(18)12-10(14)9(6-16)11(17-12)7-2-4-8(15)5-3-7/h2-5,17H,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H8BrClN2O2
Molecular Weight	339.57
AlogP	4.17
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	65.88
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	19.0

Assay Description	Organism	Bioactivity
Acaricidal activity against Tetranychus cinnabarinus (carmine spider mite) eggs assessed as mortality at 200 mg/L	Tetranychus cinnabarinus	0.0 %
Acaricidal activity against Tetranychus cinnabarinus (carmine spider mite) larvae assessed as mortality at 200 mg/L	Tetranychus cinnabarinus	40.0 %
Acaricidal activity against Tetranychus cinnabarinus (carmine spider mite) assessed as mortality at 200 mg/L	Tetranychus cinnabarinus	60.0 %
Insecticidal activity against Mythimna separata (Oriental armyworm) assessed as mortality at 25 mg/L	Mythimna separata	0.0 %
Insecticidal activity against Mythimna separata (Oriental armyworm) assessed as mortality at 50 mg/L	Mythimna separata	40.0 %
Insecticidal activity against Mythimna separata (Oriental armyworm) assessed as mortality at 100 mg/L	Mythimna separata	100.0 %
Insecticidal activity against Mythimna separata (Oriental armyworm) assessed as mortality at 200 mg/L	Mythimna separata	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2253353

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).